Chelator | Dose | Administration | Adverse effects[1] |
Succimer (also known as DMSA) | Use for acute or subacute known or suspected arsenic poisoning without encephalopathy, coma, or severe cardiovascular side effect. Oral: 10 mg/kg/dose (or 350 mg/m2/dose*) every 8 hours for 5 days, followed by 10 mg/kg/dose (or 350 mg/m2/dose*) every 12 hours for 14 days; maximum: 500 mg/dose.¶ |
| Dermatologic: Rash, pruritus Gastrointestinal: Nausea, vomiting, diarrhea, abdominal gas and pain Hematologic: Thrombocytosis, eosinophilia, hemolysis in G6PD deficiency (medium risk)[2] Hepatic: Transient elevations of hepatic aminotransferases and alkaline phosphatase concentrations Neurologic: Drowsiness, paresthesias Respiratory: Rhinorrhea, sore throat |
Unithiol (also known as DMPS); not approved by FDA for use in United StatesΔ | 5 mg/kg/dose IM:
or Regimen per product labeling (approved for mercury poisoning) IV or IM[3]:
Oral[4]: Initial (ie, has not received parenteral treatment): 1.2 to 2.4 g evenly spaced over 24 hours (eg, 100 to 200 mg every 2 hours), reduce dose based on symptoms and laboratory findings. |
| Dermatologic: Pruritus, toxic epidermal necrolysis Hematologic: Risk in G6PD deficiency unknown◊ Gastrointestinal: Nausea Immunologic: Allergic reactions Neurologic: Vertigo, weakness |
Dimercaprol (also known as British Anti-Lewisite [BAL]) Currently not being manufactured | Use for severe known or suspected arsenic poisoning with encephalopathy, coma, and/or cardiovascular toxicity. 3 to 5 mg/kg IM every 4 to 6 hours. In severe poisonings, 5 mg/kg IM every 4 hour has been used initially.[1] The goal is to transition from BAL to an oral chelator. If the patient is clinically improving but not able to take oral medications, tapering the dose is a reasonable option, such as 3 mg/kg for 2 days, then every 6 hours on day 3, followed every 12 hours for up to 10 days. |
| Formulation contains peanut oil; use with caution in peanut allergy Cardiac: Chest pain, hypertension Dermatologic: Diaphoresis Gastrointestinal: Nausea, vomiting, salivation Hematologic: Hemolysis in G6PD deficiency (high risk)[1,2] Local: Injection site pain, injection site sterile abscess Neurologic: Headache Ophthalmic: Lacrimation Respiratory: Throat pain, rhinorrhea Other: Febrile reaction, chelation of essential metals (prolonged course) |
DMPS: 2,3-dimercapto-1-propanesulfuronic acid; DMSA: meso-2,3-dimercaptosuccinic acid; G6PD: glucose 6-phosphate dehydrogenase; IM: intramuscular; IV: intravenous.
* For children <5 years dose should be based on body surface area (ie, mg/m2).
¶ Dosing is based on the use of succimer for the treatment of lead poisoning, which is only approved by the FDA for use in children with a 500 mg maximum dose. Larger doses have been used for lead and arsenic poisoning in adults. Consultation with a medical toxicologist or regional poison center is highly encouraged, especially if considering using larger doses.
Δ Intravenous and oral preparations of DMPS sodium (Brand name: Dimaval) are licensed in some countries of Europe and available for emergency use elsewhere in the world. Limited experience in children.
◊ There are case reports of hemolysis during DMPS treatment in patients with G6PD deficiency.
Prepared with additional data from: UpToDate Lexidrug. More information available at https://online.lexi.com/.